Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) announced participation in two key investor conferences. CEO Kevin Gorman and CFO Matt Abernethy will present at the Jefferies London Healthcare Conference on Nov. 16, 2021, at 1:00 p.m. GMT (8:00 a.m. ET). Additionally, CFO Abernethy and CMO Eiry Roberts will participate in the Evercore ISI 4th Annual HealthCONx Virtual Conference on Nov. 30, 2021, at 10:55 a.m. ET. Presentations will be webcast on the company’s website, with replays available for one month after each event.

News Market Reaction – NBIX

-0.22%

-0.22% Session move

In the trading session that priced this news, NBIX declined 0.22%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:

• Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer will present at the Jefferies London Healthcare Conference at 1:00 p.m. Greenwich Mean Time (8:00 a.m. Eastern Time) on Tuesday, Nov. 16, 2021 in London.
• Matt Abernethy, Chief Financial Officer, and Eiry Roberts, Chief Medical Officer, will present at the Evercore ISI 4^th Annual HealthCONx Virtual Conference at 10:55 a.m. Eastern Time on Tuesday, Nov. 30, 2021.

The live presentations will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentations will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-301420328.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

What is Neurocrine Biosciences presenting at the Jefferies London Healthcare Conference on Nov. 16, 2021?

Neurocrine Biosciences will have CEO Kevin Gorman and CFO Matt Abernethy presenting at the Jefferies London Healthcare Conference.

When is Neurocrine Biosciences presenting at the Evercore ISI 4th Annual HealthCONx Virtual Conference?

The presentation at the Evercore ISI 4th Annual HealthCONx Virtual Conference will take place on Nov. 30, 2021, at 10:55 a.m. ET.

Where can I watch the presentations by Neurocrine Biosciences?

The presentations can be watched live on Neurocrine Biosciences' website under the Investors section.

Is there a replay available for Neurocrine Biosciences' presentations?

Yes, replays of the presentations will be available on the website approximately one hour after the events.

What is the focus of Neurocrine Biosciences as a company?

Neurocrine Biosciences focuses on developing treatments for neurological, endocrine, and psychiatric disorders.